Pharmaceutical intermediates
Deucravacitinib Intermediates
9 pharmaceutical intermediates for Deucravacitinib. Indication: Plaque Psoriasis; Psoriasis.
About Deucravacitinib
- Originator
- Bristol Myers Squibb
- Indication
- Plaque Psoriasis; Psoriasis
- Approved Date
- 09/09/2022
- NCE Patent
- 09/09/2027
- DS/DP
- 11/07/2033
Available intermediates
9 intermediates currently listed for Deucravacitinib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| Ethyl 4,6-dichloropyrridazine-3-carboxylate | 679406-03-2 | / | / |
| Methyl 4,6-dichloropyridazine-3-carboxylate | 372118-01-9 | / | / |
| 2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)aniline | 1609394-10-6 | / | / |
| 4,6-dichloro-N-trideuteromethylpyridazine-3 -carboxamide | 1609393-89-6 | / | / |
| 4,6-dihydroxypyridazine-3-carboxylicacid | 1442437-21-9 | / | / |
| ethyl 4,6-dihydroxypyridazine-3-carboxylate | 1352925-63-3 | / | / |
| Methyl 4,6-dihydroxypyridazine-3-carboxylate | 372118-00-8 | / | / |
| 4,6-Dichloro-3-pyridazinecarboxylic acid, lithium salt | 2245238-80-4 | / | / |
| Lithium 4,6-Dichloropyridazine-3-carboxylate Hydrate | 2245111-15-1 | / | / |
Building toward Deucravacitinib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →